Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin

Aim: In this study we aim to identify the factors associated with treatment inertia in patients with type 2 diabetes mellitus (T2DM) who have been recently started on basal insulin (BI). Methods: Using UK CPRD GOLD, we identified adults with T2DM with suboptimal glycaemia (HbA1c within 12 months of BI ≥ 7% (≥53 mmol/mol)). We used multivariable Cox regression model to describe the association between patient characteristics and the time to treatment intensification. Results: A total of 12,556 patients were analysed. Compared to individuals aged < 65 years, those aged ≥ 65 years had lower risk of treatment intensification (HR: 0.69; 95% CI: 0.64–0.73). Other factors included being female (0.93, 0.89–0.99), longer T2DM duration (0.99, 0.98–0.99), living in the most deprived areas (0.90, 0.83–0.98), being a current smoker (0.91, 0.84–0.98), having one (0.91, 0.85–0.97) or more than one comorbidity (0.88, 0.82–0.94), and patients who were on metformin (0.71, 0.63–0.80), or 2nd generation sulphonylureas (0.85; 0.79–0.92) or DPP4 inhibitors (0.87, 0.82–0.93) compared to those who were not. Conclusion: Therapeutic inertia still remains a major barrier, with multiple factors associated with delay in intensification. Interventions to overcome therapeutic inertia need to be implemented at both patient and health care professional level.